Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019865 | 0.86 | HSD17B10 (0.55) | HSD17B10KMT2AMEN1SIGMAR1GLS | |
| SCHEMBL171970 | 0.86 | KMT2A (0.59) | HSD17B10KMT2AMEN1GLSALDH1A1 | |
| SCHEMBL17993524 | 0.85 | HSD17B10 (0.60) | HSD17B10KMT2AMEN1SIGMAR1GLS | |
| SCHEMBL13619977 | 0.82 | ATM (0.59) | KMT2AMEN1GLSGAATAAR1 | |
| SCHEMBL13485784 | 0.80 | HSD17B10 (0.69) | HSD17B10KMT2AMEN1SIGMAR1GLS | |
| SCHEMBL2826592 | 0.79 | HSD17B10 (0.67) | HSD17B10KMT2AMEN1SIGMAR1GLS | |
| SCHEMBL6500250 | 0.79 | HSD17B10 (0.67) | HSD17B10KMT2AMEN1SIGMAR1GLS | |
| SCHEMBL169824 | 0.79 | TDP1 (0.76) | KMT2AMEN1GAATDP1NPSR1 | |
| SCHEMBL171948 | 0.78 | KMT2A (0.78) | KMT2AMEN1GAATDP1ALDH1A1 | |
| SCHEMBL30104106 | 0.76 | HSD17B10 (0.73) | HSD17B10KMT2AMEN1GLSMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HSD17B10 2594/4885KMT2A 938/4885MEN1 1071/4885 |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HSD17B10 3782/4885KMT2A 2353/4885MEN1 3231/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | HSD17B10 2594/4885KMT2A 938/4885MEN1 1071/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HSD17B10 3782/4885KMT2A 2353/4885MEN1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.